- Home
- PLX vs PERF Comparison
PLX vs PERF Comparison
Compare PLX & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- PERF
- Stock Information
- Founded
- PLX 1993
- PERF 2015
- Country
- PLX United States
- PERF Taiwan
- Employees
- PLX N/A
- PERF N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- PERF Computer Software: Prepackaged Software
- Sector
- PLX Health Care
- PERF Technology
- Exchange
- PLX Nasdaq
- PERF Nasdaq
- Market Cap
- PLX 204.9M
- PERF 205.7M
- IPO Year
- PLX 1998
- PERF N/A
- Fundamental
- Price
- PLX $1.85
- PERF $1.94
- Analyst Decision
- PLX Strong Buy
- PERF Buy
- Analyst Count
- PLX 1
- PERF 1
- Target Price
- PLX $15.00
- PERF $5.00
- AVG Volume (30 Days)
- PLX 1.1M
- PERF 168.7K
- Earning Date
- PLX 11-13-2025
- PERF 10-28-2025
- Dividend Yield
- PLX N/A
- PERF N/A
- EPS Growth
- PLX N/A
- PERF 4.52
- EPS
- PLX 0.08
- PERF 0.06
- Revenue
- PLX $61,948,000.00
- PERF $64,369,000.00
- Revenue This Year
- PLX $14.53
- PERF $15.99
- Revenue Next Year
- PLX $75.77
- PERF $14.39
- P/E Ratio
- PLX $24.02
- PERF $32.17
- Revenue Growth
- PLX 62.79
- PERF 13.19
- 52 Week Low
- PLX $1.01
- PERF $1.51
- 52 Week High
- PLX $3.10
- PERF $3.44
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- PERF 48.36
- Support Level
- PLX $2.31
- PERF $1.87
- Resistance Level
- PLX $2.55
- PERF $1.95
- Average True Range (ATR)
- PLX 0.15
- PERF 0.10
- MACD
- PLX -0.06
- PERF 0.00
- Stochastic Oscillator
- PLX 23.70
- PERF 42.76
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.